TS 01

Drug Profile

TS 01

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Beth Israel Deaconess Medical Center; Harvard Medical School
  • Developer Thrombolytic Science International
  • Class Complement C1 inactivator proteins; Recombinant proteins; Thrombolytics
  • Mechanism of Action Urokinase-type plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke(In volunteers) in Netherlands (Parenteral)
  • 27 Jun 2015 Thrombolytic Corporation plans a phase IIa trial in stroke in USA
  • 01 Jun 2015 Thrombolytic Corporation signs a CRADA with National Institute of Neurological Disorders and Stroke for the treatment of stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top